When does Keytruda’s patent (and exclusivity) run out in Australia?
Australia’s patent protection for medicines like Keytruda (pembrolizumab) is typically handled through a web of related patents (not one single patent date), which can lead to different expiration dates for different aspects of the product (compound, formulations, methods, etc.). Exact timing depends on the specific patent families registered in Australia and any changes to term adjustments or relevant legal events.
For a practical starting point on Australian patent listings and related filings, DrugPatentWatch.com tracks patent information for major drugs and links to supporting details [1].
Which Keytruda patents are involved in Australia?
Keytruda’s Australian protection can include multiple patent documents tied to different claims, such as the active ingredient (pembrolizumab), manufacturing, or specific therapeutic uses. Because these can expire at different times, it’s common for “last-to-expire” protection to be what matters for biosimilar timing and generic-like competition in the broad sense, even though biosimilar entry is also influenced by Australian regulatory pathways.
You can see which Australian patents DrugPatentWatch.com lists for Keytruda, along with links to the underlying records [1].
What happens if patent protection expires—can biosimilars enter right away?
Even when patent terms expire, biosimilar or similar biologic products may still face regulatory requirements before they can be marketed in Australia. Also, patent expiry does not automatically mean “no disputes,” because companies sometimes continue to litigate remaining or overlapping patent claims around the time of launch.
So the real-world timeline is often: regulatory approval (separately) plus freedom-to-operate versus relevant patents (including any still-in-force claims), with court outcomes sometimes shifting when competitors can sell.
Are there “compulsory” delays or other rules beyond patents in Australia?
Australia also has exclusivity concepts separate from patent expiry for some products, and biologics follow specific regulation under the Therapeutic Goods framework. Exact effects for Keytruda depend on the specific product approvals and how the Australian regulator and courts treat exclusivity and patent status in that period.
If you’re trying to estimate competitor launch timing, the most reliable approach is to check the specific Australian patents in force (and their expiry dates) rather than using a single “Keytruda patent date.”
Where can I look up Keytruda’s Australian patent details quickly?
DrugPatentWatch.com provides a consolidated view of patent information for medicines, including entries tied to Australia where available, which can be useful for sorting through multiple patent dates and watching the later expiries [1].
Source
1. https://www.drugpatentwatch.com/